Mass cytometry for comprehensive immune profiling in CAR T cell

Cell & Gene Therapy Insights 2021; 7(10), 1465–1470


Published: 18 November 2021
Sneha Ramakrishna

Sneha Ramakrishna

Instructor, Pediatrics - Hematology & Oncology, Stamford

“Evaluating multiple clinically relevant timepoints, from apheresis through post-infusion timepoints, will be invaluable for identifying the most desirable and functional CAR T cell populations and may provide insight into potential approaches to optimize CAR T cell therapies for the future.”